Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Dow
Mallinckrodt
Medtronic
Express Scripts

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR RISPERIDONE


✉ Email this page to a colleague

« Back to Dashboard

505(b)(2) Clinical Trials for Risperidone

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Indication NCT01770600 ↗ Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression Withdrawn University of Alabama at Birmingham N/A 2010-04-01 This study is dedicated to achieving a better understanding of how the brain processes information. Specifically, the investigators are studying cognitive function, thought process, and impulsivity in people with and without suicidal thoughts. You are being asked to participate in a research study to learn how the use of a medication, risperidone, improves your symptoms of depression. Specifically the investigators are studying the effectiveness of reducing the thought of suicide and other symptoms of severe depression. Risperidone is approved by FDA for the treatment of schizophrenia and bipolar mania, and clinical practice suggests that it might benefit patients with major depressive disorder. During clinical trials with 2607 patients, risperidone was proved to be safe. This is a pilot study to test a new indication of risperidone for treatment of severe depression. The study medication will be given in addition to usual psychiatric care.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Risperidone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000267 ↗ Risperidone Treatment in Dually-Diagnosed Individuals - 2 Completed New York State Psychiatric Institute Phase 2 1969-12-31 The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
NCT00000267 ↗ Risperidone Treatment in Dually-Diagnosed Individuals - 2 Completed National Institute on Drug Abuse (NIDA) Phase 2 1969-12-31 The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
NCT00000272 ↗ Early Phase II Trials for Cocaine Medication Development - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 1996-08-01 The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This
NCT00000272 ↗ Early Phase II Trials for Cocaine Medication Development - 1 Completed New York State Psychiatric Institute Phase 2 1996-08-01 The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This
NCT00000272 ↗ Early Phase II Trials for Cocaine Medication Development - 1 Completed Research Foundation for Mental Hygiene, Inc. Phase 2 1996-08-01 The purpose of this study is to develop models for early Phase II testing of potential medications for cocaine dependence: amoxapine, risperidone and other agents. The study was a controlled pilot trial of risperidone in opiate-dependent patients on methadone maintenance. The study explored whether risperidone reduced cocaine use, cocaine craving, and cocaine subjective effects in patients on methadone maintenance who abused cocaine and whether it had an acceptable side effect profile. This
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Risperidone

Condition Name

Condition Name for Risperidone
Intervention Trials
Schizophrenia 309
Schizoaffective Disorder 64
Bipolar Disorder 51
Psychotic Disorders 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Risperidone
Intervention Trials
Schizophrenia 336
Psychotic Disorders 131
Disease 117
Mental Disorders 74
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Risperidone

Trials by Country

Trials by Country for Risperidone
Location Trials
China 71
Canada 56
India 43
Spain 42
Germany 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Risperidone
Location Trials
California 109
New York 90
Texas 76
Florida 61
Ohio 60
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Risperidone

Clinical Trial Phase

Clinical Trial Phase for Risperidone
Clinical Trial Phase Trials
Phase 4 182
Phase 3 131
Phase 2/Phase 3 9
[disabled in preview] 86
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Risperidone
Clinical Trial Phase Trials
Completed 405
Terminated 50
Unknown status 48
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Risperidone

Sponsor Name

Sponsor Name for Risperidone
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 47
National Institute of Mental Health (NIMH) 40
Janssen, LP 39
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Risperidone
Sponsor Trials
Other 508
Industry 362
NIH 63
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Dow
Express Scripts
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.